Malek Kamoun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11305177/publications.pdf Version: 2024-02-01



MALEK KAMOUN

#	Article	IF	CITATIONS
1	HLA antigens to epitopes: Meeting the challenge. Human Immunology, 2022, 83, 270-271.	2.4	3
2	Incidence of acute rejection and patient survival in combined heart–liver transplantation. Liver Transplantation, 2022, 28, 1500-1508.	2.4	2
3	Phase 3 trial of human islet-after-kidney transplantation in type 1 diabetes. American Journal of Transplantation, 2021, 21, 1477-1492.	4.7	64
4	Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT Outcomes. Transplantation and Cellular Therapy, 2021, 27, 142.e1-142.e11.	1.2	3
5	Successful transatlantic bilateral hand transplant in a young female highly sensitized to HLA class II antigens. Transplant Immunology, 2021, 65, 101377.	1.2	1
6	Genetics of HLA Peptide Presentation and Impact on Outcomes in HLA-Matched Allogeneic Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 591-599.	1.2	4
7	Lung transplantation outcomes after crossing lowâ€level donor specific antibodies without planned augmented immunosuppression. Clinical Transplantation, 2021, 35, e14447.	1.6	7
8	BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization. Transplant Immunology, 2021, 69, 101465.	1.2	7
9	Immunogenetics of heteroclitic recognition of HLA-DQB1 55R eplet specificity by human alloantibody. Human Immunology, 2021, 83, 99-99.	2.4	Ο
10	The impact of belatacept on third-party HLA alloantibodies in highly sensitized kidney transplant recipients. American Journal of Transplantation, 2020, 20, 573-581.	4.7	19
11	The impact of HLA-DR mismatch status on retransplant-free survival and bronchiolitis obliterans syndrome‒free survival among sensitized lung transplant recipients. Journal of Heart and Lung Transplantation, 2020, 39, 1455-1462.	0.6	9
12	A blueprint for electronic utilization of ambiguous molecular HLA typing data in organ allocation systems and virtual crossmatch. Human Immunology, 2020, 81, 65-72.	2.4	4
13	Class and Kinetics of Weakly Reactive Pretransplant Donor-specific HLA Antibodies Predict Rejection in Kidney Transplant Recipients. Transplantation Direct, 2019, 5, e478.	1.6	7
14	Computational assessment of miRNA binding to low and high expression HLA-DPB1 allelic sequences. Human Immunology, 2019, 80, 53-61.	2.4	14
15	An ultra-low-cost smartphone octochannel spectrometer for mobile health diagnostics. Journal of Biophotonics, 2018, 11, e201700382.	2.3	19
16	Human leukocyte antigens antibodies after lung transplantation: Primary results of the HALT study. American Journal of Transplantation, 2018, 18, 2285-2294.	4.7	48
17	Analytical validation of an ultra low-cost mobile phone microplate reader for infectious disease testing. Clinica Chimica Acta, 2018, 482, 21-26.	1.1	12
18	Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care, 2018, 41, 1001-1008.	8.6	89

Malek Kamoun

#	Article	IF	CITATIONS
19	Fatal accelerated rejection with a prominent natural killer cell infiltrate in a heart transplant recipient with peripartum cardiomyopathy. Transplant Immunology, 2018, 47, 49-54.	1.2	1
20	The new KAS: Challenges and opportunities. Human Immunology, 2017, 78, 54-56.	2.4	3
21	HLA Amino Acid Polymorphisms and Kidney Allograft Survival. Transplantation, 2017, 101, e170-e177.	1.0	23
22	Histopathologic changes in anti-angiotensin II type 1 receptor antibody-positive kidney transplant recipients with acute rejection and no donor specific HLA antibodies. Human Immunology, 2017, 78, 350-356.	2.4	13
23	Improving the antibody-based evaluation of autoimmune encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e404.	6.0	70
24	Assessing a single targeted next generation sequencing for human leukocyte antigen typing protocol for interoperability, as performed by users with variable experience. Human Immunology, 2017, 78, 642-648.	2.4	11
25	The new KAS: It takes a village. Human Immunology, 2017, 78, 1-3.	2.4	Ο
26	An Expanded Role for HLA Genes: HLA-B Encodes a microRNA that Regulates IgA and Other Immune Response Transcripts. Frontiers in Immunology, 2017, 8, 583.	4.8	57
27	Laboratory Medicine Education at U.S. Medical Schools. Academic Medicine, 2016, 91, 107-112.	1.6	33
28	OR45 RNA sequencing of two lymphoblastoid cell lines reveals novel microrna transcripts of the MHC. Human Immunology, 2016, 77, 38.	2.4	2
29	Successful long-term outcomes in combined heart-liver transplants across pre-formed high levels of donor-specific antibodies in highly sensitized patients. Journal of Heart and Lung Transplantation, 2016, 35, 1382-1384.	0.6	10
30	Correlation of Circulating Complement-Fixing Donor-Specific Antibodies Identified by the C1q Assay and Presence of C4d in Endomyocardial Biopsy Specimens. American Journal of Clinical Pathology, 2016, 145, 62-68.	0.7	6
31	Concept and design of a genome-wide association genotyping array tailored for transplantation-specific studies. Genome Medicine, 2015, 7, 90.	8.2	49
32	Correlations of lymphocyte subset infiltrates with donor-specific antibodies and acute antibody-mediated rejection in endomyocardial biopsies. Cardiovascular Pathology, 2015, 24, 168-172.	1.6	12
33	Association of HLA-DRB1 genetic variants with the persistence of atopic dermatitis. Human Immunology, 2015, 76, 571-577.	2.4	15
34	Transplant Nephrectomy: Histologic Findings - A Single Center Study. American Journal of Nephrology, 2014, 40, 491-498.	3.1	3
35	Clinical outcomes among renal transplant recipients with preâ€transplant weakly reactive donorâ€specific antibodies. Clinical Transplantation, 2014, 28, 127-133.	1.6	10
36	Circulating Donor-Specific Anti–Human Leukocyte Antigen Antibodies and Complement C4d Deposition Are Associated With the Development of Cardiac Allograft Vasculopathy. American Journal of Clinical Pathology, 2014, 142, 809-815.	0.7	41

Malek Kamoun

#	Article	IF	CITATIONS
37	Improvement in Î ² -Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol. Diabetes, 2013, 62, 2890-2897.	0.6	93
38	Protein phosphatase 2A family members (PP2A and PP6) associate with U1 snRNP and the spliceosome during pre-mRNA splicing. Biochemical and Biophysical Research Communications, 2013, 440, 306-311.	2.1	16
39	Correlation of circulating donor-specific anti-HLA antibodies and presence of C4d in endomyocardial biopsy with heart allograft outcomes: A single-center, retrospective study. Journal of Heart and Lung Transplantation, 2013, 32, 410-417.	0.6	36
40	Electronically measured adherence to immunosuppressive medications and kidney function after deceased donor kidney transplantation. Clinical Transplantation, 2011, 25, E124-31.	1.6	14
41	Educating Medical Students in Laboratory Medicine. American Journal of Clinical Pathology, 2010, 133, 533-542.	0.7	71
42	Expression of 3G11 epitope defines subpopulations of regulatory T cells with different suppressive potency. Journal of the Neurological Sciences, 2010, 295, 66-74.	0.6	3
43	HLA-A amino acid polymorphism and delayed kidney allograft function. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18883-18888.	7.1	14
44	Evidence for Allograft Rejection in an Islet Transplant Recipient and Effect on β-Cell Secretory Capacity. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2410-2414.	3.6	36
45	Mechanisms of Chronic Allograft Dysfunction. Therapeutic Drug Monitoring, 2006, 28, 14-18.	2.0	5
46	Analysis of the CD2 and spliceosomal Sm B/B′ polyproline-arginine motifs defined by a monoclonal antibody using a phage-displayed random peptide library. Journal of Molecular Recognition, 2006, 19, 535-541.	2.1	1
47	Loss of the Surface Antigen 3G11 Characterizes a Distinct Population of Anergic/Regulatory T Cells in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2006, 176, 3366-3373.	0.8	11
48	Race and Electronically Measured Adherence to Immunosuppressive Medications after Deceased Donor Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 1839-1848.	6.1	169
49	IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences, 2005, 232, 3-9.	0.6	69
50	Early administration of IL-12 suppresses EAE through induction of interferon-Î ³ . Journal of Neuroimmunology, 2004, 156, 123-131.	2.3	53
51	Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. Journal of the Neurological Sciences, 2003, 215, 95-103.	0.6	76
52	Parallel purification of three catalytic subunits of the protein serine/threonine phosphatase 2A family (PP2AC, PP4C, and PP6C) and analysis of the interaction of PP2AC with alpha4 protein. Protein Expression and Purification, 2003, 31, 19-33.	1.3	63
53	Induction of Experimental Autoimmune Encephalomyelitis in IL-12 Receptor-β2-Deficient Mice: IL-12 Responsiveness Is Not Required in the Pathogenesis of Inflammatory Demyelination in the Central Nervous System. Journal of Immunology, 2003, 170, 2153-2160.	0.8	282
54	Role of IL-12 Receptor β1 in Regulation of T Cell Response by APC in Experimental Autoimmune Encephalomyelitis. Journal of Immunology, 2003, 171, 4485-4492.	0.8	83

#	Article	IF	CITATIONS
55	IL-12p35-Deficient Mice Are Susceptible to Experimental Autoimmune Encephalomyelitis: Evidence for Redundancy in the IL-12 System in the Induction of Central Nervous System Autoimmune Demyelination. Journal of Immunology, 2002, 169, 7104-7110.	0.8	363
56	HLA Class I typing of volunteers for a bone marrow registry: QC analysis by DNA-based methodology identifies serological typing discrepancies in the assignment of HLA-A and B antigens. Tissue Antigens, 2002, 59, 211-215.	1.0	14
57	Mechanisms of Suppression of Experimental Autoimmune Encephalomyelitis by Intravenous Administration of Myelin Basic Protein: Role of Regulatory Spleen Cells. Experimental and Molecular Pathology, 2000, 68, 29-37.	2.1	26
58	Hepatosplenic gamma-delta T-Cell Lymphoma as a Late-Onset Posttransplant Lymphoproliferative Disorder in Renal Transplant Recipients. American Journal of Clinical Pathology, 2000, 113, 487-496.	0.7	56
59	Reduced Mobilization of CD34+Stem Cells in Advanced Human Immunodeficiency Virus Type 1 Disease. Journal of Infectious Diseases, 2000, 181, 148-157.	4.0	33
60	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 279-288.	1.1	15
61	Identification of a type 6 protein Ser/Thr phosphatase regulated by interleukin-2 stimulation. Journal of Cellular Biochemistry, 1999, 73, 153-163.	2.6	13
62	Monoclonal antibody specific to a subclass of polyproline-arg motif provides evidence for the presence of an snRNA-free spliceosomal Sm protein complex in vivo: Implications for molecular interactions involving proline-rich sequences of Sm B/B? proteins. Journal of Cellular Biochemistry, 1999, 74, 168-180.	2.6	5
63	Evidence for Early Hematopoietic Progenitor Cell Involvement in Acute Promyelocytic Leukemia. American Journal of Clinical Pathology, 1999, 112, 819-827.	0.7	39
64	Association of p59 with the T Lymphocyte Costimulatory Receptor CD2. Journal of Biological Chemistry, 1998, 273, 19914-19921.	3.4	32
65	Hepatosplenic Î ³ Î′ T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation. Human Pathology, 1997, 28, 674-685.	2.0	82
66	Genetic polymorphism of the human tumor necrosis factor region in insulin-dependent diabetes mellitus linkage disequilibrium of TNFab microsatellite alleles with HLA haplotypes. Human Immunology, 1995, 44, 70-79.	2.4	52
67	Diminished tyrosine protein kinase activity in T cells unresponsive to TCR stimulation. Journal of Leukocyte Biology, 1994, 55, 289-298.	3.3	14
68	Laboratory Medicine Education in United States Medical Schools. American Journal of Clinical Pathology, 1993, 100, 594-598.	0.7	19
69	Interleukin-4 differentially regulates interleukin-2-mediated and CD2-mediated induction of human lymphokine-activated killer effectors. European Journal of Immunology, 1992, 22, 2861-2865.	2.9	9
70	Biochemical and Genomic Characterization of HLA-DQ Gene Products Associated with DR3, DR4, and DR5 Haplotypes. , 1989, , 296-297.		0
71	Analysis of DR and DQ gene products of the DR4 haplotype in patients with IDDM: Possible involvement of more than one locus. Human Immunology, 1988, 23, 289-299.	2.4	15
72	Carbohydrate Differences in HLA-DR Molecules Synthesized by Alveolar Macrophages and Blood Monocytes ^{1–} ³ . The American Review of Respiratory Disease, 1987, 135, 1340-1344.	2.9	25

#	Article	IF	CITATIONS
73	HLA-DQw3.2 allele of the DR4 haplotype is associated with insulin-dependent diabetes; correlation between DQ ? restriction fragments and DQ ? chain variation. Immunogenetics, 1987, 26, 299-303.	2.4	33
74	B-Lymphoid cell lines derived fromHLA-D homozygous donors. Immunogenetics, 1979, 8, 51-64.	2.4	67
75	Induction of HLA expression in Daudi cells after cell fusion. Immunogenetics, 1977, 5, 423-436.	2.4	84